Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey

Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey

Bibliographic Details
Main Authors:	Marlene Stoll, Lara Hubenschmid, Cora Koch, Klaus Lieb, Boris Egloff
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-06-01
Series:	BMJ Open
Online Access:	https://bmjopen.bmj.com/content/12/6/e055963.full

Similar Items

Voluntary disclosures of payments from pharmaceutical companies to healthcare professionals in Germany: a descriptive study of disclosures in 2015 and 2016
by: Marlene Stoll, et al.
Published: (2020-09-01)

Characteristics of physicians receiving large payments from pharmaceutical companies and the accuracy of their disclosures in publications: an observational study
by: Norris Susan L, et al.
Published: (2012-09-01)

International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
by: Piotr Ozieranski, et al.
Published: (2023-03-01)

Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database.
by: Piotr Ozieranski, et al.
Published: (2023-01-01)

Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database
by: Piotr Ozieranski, et al.
Published: (2023-01-01)

Are Pharmaceutical Company Payments Incentivising Malpractice in Japanese Physicians?
by: Yurie Kobashi, et al.
Published: (2019-10-01)

The importance of “disclosure” in relationships between physicians and pharmaceutical companies
by: Marta Makowska, et al.
Published: (2018-07-01)

The impact of using electronic payment methods on transparency and disclosure: Case study Jordanian companies
by: Aridah MAMOUN WALID, et al.
Published: (2020-06-01)

Development of a checklist for evaluating psychiatric reports
by: Nadine Dreimüller, et al.
Published: (2019-05-01)

Voluntary disclosure in the biotechnology industry
by: Pan, Grace Meiyun, et al.
Published: (2008)

Comparison of voluntary disclosure in Singapore.
by: Chan, Jean Siew Chen., et al.
Published: (2008)

Female dermatology journal editors accepting pharmaceutical payments: An analysis of the Open Payments database, 2013 to 2018
by: Waqas Haque, MPH, MPhil, et al.
Published: (2021-09-01)

Interessenkonflikte im Medizinstudium. Fehlende Regulierung und hoher Informationsbedarf bei Studierenden an den meisten deutschen Universitäten
by: Lieb, Klaus, et al.
Published: (2014-02-01)

Capitalizing on transparency: Commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act
by: Shai Mulinari, et al.
Published: (2022-01-01)

Understanding voluntary disclosure: Malaysian perspective
by: Zaini Embong,
Published: (2014)

Corporate governance and voluntary disclosure in Malaysia
by: Mohd Ghazali, Nazli Anum
Published: (2010)

Voluntary Disclosures of Indian Microfinance Institutions
by: Arpita Sharma, et al.
Published: (2022-07-01)

Corporate Governance Mechanisms and Voluntary Disclosure
by: Erwin Saraswati, et al.
Published: (2020-10-01)

Impact of economic recession on voluntary disclosure.
by: Cheng, Lay Boon., et al.
Published: (2008)

Voluntary disclosure of listed companies in Singapore.
by: Chang, Mun Ling., et al.
Published: (2008)

Voluntary disclosure and the volatility of security returns.
by: Chia, Chye Hua., et al.
Published: (2008)

Voluntary disclosure of financial information on the Internet.
by: Chua, Shuh Luan., et al.
Published: (2008)

The Effect of CEO Narcissism on Voluntary Disclosure
by: Shahnaz Mashayekh, et al.
Published: (2021-02-01)

Effects of enterprise risk management on voluntary disclosure and voluntary risk reporting.
by: Chow, Mun Jun., et al.
Published: (2008)

Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries
by: Alice Fabbri, et al.
Published: (2018-06-01)

Industry payments to family medicine residents in Portugal: a descriptive analysis of the national transparency database
by: Marta Ruivo, et al.
Published: (2023-08-01)

Does price disclosure in pharmaceutical advertising result in price transparency? Evidence from a randomized experiment
by: Ilene L. Hollin, et al.
Published: (2022-12-01)

The Role of Theory in Explaining Motivation for Corporate Social Disclosures: Voluntary Disclosures vs ‘Solicited’ Disclosures
by: Sandra van der Laan
Published: (2009-12-01)

Voluntary Transparency in Spanish University Libraries
by: Ana R. Pacios, et al.
Published: (2022-05-01)

Disclosure of nanomaterials under nanotechnology product inventory, voluntary certification, and voluntary labelling
by: Hasmin, N. A., et al.
Published: (2021)

The Effectiveness of the Voluntary Disclosure Program in Enhancing Voluntary Compliance among Individual Taxpayers
by: Erma Yunita, et al.
Published: (2023-09-01)

Essays on voluntary disclosure, information uncertainty and investment
by: Song, Q
Published: (2023)

Voluntary disclosure in Malaysian corporate annual reports
by: Mohd Ghazali, Nazli Anum
Published: (2009)

Factors influencing corporate voluntary disclosures in Malaysia
by: Ahmed Haji, Abdifatah, et al.
Published: (2013)

Determinants of Voluntary Disclosure in Iran Capital Marke
by: Ali Rahmani, et al.
Published: (2017-12-01)

Corporate voluntary disclosure practices of banks in Bangladesh
by: Al Mamun, Syed Abdulla, et al.
Published: (2014)

Voluntary disclosure regime and its motivating factors
by: Chai, Ping Fong, et al.
Published: (2008)

Voluntary information disclosure in company annual reports
by: C. Firer, et al.
Published: (1985-12-01)

Effects of corporate governance mechanisms on voluntary disclosure.
by: Geetha Sivaramakrishnam., et al.
Published: (2008)

The value relevance of extent and sophistication of voluntary disclosure.
by: Foo, Yin Ling., et al.
Published: (2008)